EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Pre‐emptive pharmacogenomics testing in clinical practice: A pilot implementation in Singapore

Elaine Ah Gi Lo, Hui Min Chua, Dennis Chua, Huang En Toh, Evelyn Shi Jie Tan, Golda Wang, Min Yi Gwee, Amanda Lay Ying Lim, Christina Jiun Yu Tan, Siok Ying Lee, Jing Wen Oh, Pei Shieen Wong, Lawrence Siu‐Chun Law, Ken Juin Lim, Jishana Farhad Abdul Naseer, Humphrey Hean Teik Ko, Boon Cher Goh, Benjamin Yong‐Qiang Tan, Yi Min Wan, Fathima Ashna Nastar, Rangpa Taiju, Khai Pang Leong, Liuh Ling Goh, Teck Choon Tan, Syed Saqib Imran, Kaavya Narasimhalu, Joanne Ngeow, Zewen Zhang, Kee Yuan Ngiam, Patrick Tan, Ee Shien Tan, Doreen Low, Hwee Lin Wee, E. Shyong Tai, Jared D'Souza

British Journal of Clinical Pharmacology · 2026-11-05

DOI: 10.1002/bcp.70889 ↗
AbstractBibliografische Angaben

Abstract

Aims Pre‐emptive pharmacogenomics (PPGx) testing holds promise for optimizing drug therapy, but uptake remains limited in Asia. This pilot study aimed to assess the feasibility of PPGx uptake into clinical practice and its impact on prescribing in an Asian healthcare setting. Methods A prospective, multicentre pilot study was conducted to pre‐emptively genotype 16 pharmacogenes. Results were integrated into electronic health records, alongside deployment of clinical decision support (CDS) tools for 31 drug–gene pairs. A pharmacogenomics drug information service and digital platforms were also developed. Results All 2492 participants carried ≥1 actionable variant (median: 5, range: 1–11). Across four institutions within one cluster, 1046 out of 2238 (46.7%) patients were prescribed ≥1 drug with pharmacogenetic association, and of those, 460 (44%) had genotypes linked to undesirable drug responses. Among 285 interruptive CDS alerts, 69 (24.2%) led to prescription modifications. Acceptance was higher for new prescriptions (50.0% vs . 17.3%, p < 0.001), in outpatient settings (31.0% vs . 7.3%, p < 0.001) and among consultants (57.1% vs . other designations 5–27.3%, p < 0.001). The drug information service received 137 enquiries, while 471 and 151 patients accessed the app and web‐based platforms respectively. Conclusions PPGx testing and genotype‐guided prescribing are feasible in Singapore. Widespread adoption requires leadership support, robust informatics infrastructure, clinician engagement and sustainable funding.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →